Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04594694
Registration number
NCT04594694
Ethics application status
Date submitted
14/07/2020
Date registered
20/10/2020
Date last updated
18/04/2024
Titles & IDs
Public title
Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC
Query!
Scientific title
A Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination With Bezafibrate in Subjects With Primary Biliary Cholangitis Who Had an Inadequate Response or Who Were Unable to Tolerate Ursodeoxycholic Acid
Query!
Secondary ID [1]
0
0
747-213
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Primary Biliary Cholangitis
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Obeticholic acid
Treatment: Drugs - Bezafibrate 200 MG
Treatment: Drugs - OCA Placebo
Treatment: Drugs - Bezafibrate 200 mg Placebo
Treatment: Drugs - Bezafibrate 400 MG
Treatment: Drugs - Bezafibrate 400 mg Placebo
Treatment: Drugs - OCA
Treatment: Drugs - Bezafibrate
Active Comparator: Treatment A: BZF 200 milligrams (mg) Immediate release (IR) - Participants will receive Bezafibrate (BZF) 200 mg IR + OCA Placebo + BZF 400 mg Placebo
Active Comparator: Treatment B: BZF 400 mg SR - Participants will receive BZF 400 mg SR + OCA Placebo + BZF 200 mg Placebo
Experimental: Treatment C: OCA 5 mg to 10 mg + BZF 200 mg IR - Participants will receive OCA 5 mg to 10 mg + BZF 200 mg IR + BZF 400 mg Placebo
Experimental: Treatment D: OCA 5 mg to 10 mg + BZF 400 mg SR - Participants will receive OCA 5 mg to 10 mg + BZF 400 mg SR + BZF 200 mg Placebo
Experimental: Long-term safety extension (LTSE) phase: OCA + BZF - Participants will continue the original treatment assignment allocated during the DB Period. The OCA and BZF dose may be optimized based on safety and efficacy during the DB period.
Treatment: Drugs: Obeticholic acid
5 mg tablet of OCA once daily titrating up to a maximum of 10 mg OCA once daily
Treatment: Drugs: Bezafibrate 200 MG
200 mg IR tablet of Bezafibrate once daily for the remainder of the study
Treatment: Drugs: OCA Placebo
One tablet daily for the remainder of the study
Treatment: Drugs: Bezafibrate 200 mg Placebo
One tablet daily for the remainder of the study
Treatment: Drugs: Bezafibrate 400 MG
400 mg SR tablet of Bezafibrate once daily for the remainder of the study
Treatment: Drugs: Bezafibrate 400 mg Placebo
One tablet daily for the remainder of the study
Treatment: Drugs: OCA
OCA one tablet will be administered.
Treatment: Drugs: Bezafibrate
Bezafibrate one tablet will be administered.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change in Alkaline Phosphatase (ALP) from baseline to Week 12 in the DB Treatment Period
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Baseline, Day 1, and Weeks 4, 8, and 12
Query!
Secondary outcome [1]
0
0
Response rates of =10%, =20%, =30% and =40% reduction, and normalization of biochemical disease marker Alkaline Phosphatase (ALP)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Baseline, Day 1, and Weeks 2, 4, 6, 8, and 12
Query!
Secondary outcome [2]
0
0
Number of participants with normalization rates of biochemical disease marker Alanine Aminotransferase (ALT), Gamma-Glutamyl Transpeptidase (GGT), Aspartate Aminotransferase (AST), total and conjugated bilirubin and lipid panel
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Baseline, Day 1, and Weeks 2, 4, 6, 8, and 12
Query!
Secondary outcome [3]
0
0
Change in GGT from baseline to Week 12
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Baseline, Day 1, and Weeks 4, 8, and 12
Query!
Secondary outcome [4]
0
0
Change in ALT from baseline to Week 12
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Baseline, Day 1, and Weeks 4, 8, and 12
Query!
Secondary outcome [5]
0
0
Change in AST from baseline to Week 12
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Baseline, Day 1, and Weeks 4, 8, and 12
Query!
Secondary outcome [6]
0
0
Change in total and conjugated bilirubin from baseline to Week 12
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Baseline, Day 1, and Weeks 4, 8, and 12
Query!
Secondary outcome [7]
0
0
Change in lipid panel from baseline to Week 12
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Baseline, Day 1, and Weeks 4, 8, and 12
Query!
Secondary outcome [8]
0
0
Change in 7 alpha (a) hydroxy 4 cholesten-3 one (C4) from baseline to Week 12
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Baseline, Day 1, and Weeks 4, 8, and 12
Query!
Secondary outcome [9]
0
0
Change in bile acid from baseline to Week 12
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
Baseline, Day 1, and Weeks 4,8, and 12
Query!
Eligibility
Key inclusion criteria
- A definite or probable diagnosis of PBC
- Qualifying ALP and/or bilirubin liver biochemistry values
- Taking Ursodeoxycholic Acid (UDCA) for at least 12 months or no UDCA for 3 months
before Day 1
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- History or presence of other concomitant liver diseases
- Clinical complications of PBC
- History or presence of hepatic decompensating events
- Current or history of gallbladder disease
- If female, known pregnancy, or has a positive urine pregnancy test (confirmed by a
positive serum pregnancy test), or lactating
- Treatment with commercially available OCA or other farnesoid X receptor (FXR)
agonists, or participation in a previous study involving OCA within 3 months before
Screening.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
2/10/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/12/2025
Query!
Actual
Query!
Sample size
Target
72
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Pert
Query!
Recruitment hospital [1]
0
0
Flinders Medical Centre - Bedford Park
Query!
Recruitment hospital [2]
0
0
Royal Adelaide Hospital - Adelaide
Query!
Recruitment postcode(s) [1]
0
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [2]
0
0
5000 - Adelaide
Query!
Recruitment outside Australia
Country [1]
0
0
Belgium
Query!
State/province [1]
0
0
Leuven
Query!
Country [2]
0
0
Croatia
Query!
State/province [2]
0
0
Zagreb
Query!
Country [3]
0
0
Czechia
Query!
State/province [3]
0
0
Hradec Kralove
Query!
Country [4]
0
0
Czechia
Query!
State/province [4]
0
0
Ostrava
Query!
Country [5]
0
0
Czechia
Query!
State/province [5]
0
0
Plzen
Query!
Country [6]
0
0
Estonia
Query!
State/province [6]
0
0
Tartu
Query!
Country [7]
0
0
France
Query!
State/province [7]
0
0
Créteil
Query!
Country [8]
0
0
France
Query!
State/province [8]
0
0
Grenoble
Query!
Country [9]
0
0
France
Query!
State/province [9]
0
0
Lille
Query!
Country [10]
0
0
France
Query!
State/province [10]
0
0
Paris
Query!
Country [11]
0
0
Germany
Query!
State/province [11]
0
0
Hamburg
Query!
Country [12]
0
0
Germany
Query!
State/province [12]
0
0
Hannover
Query!
Country [13]
0
0
Greece
Query!
State/province [13]
0
0
Larissa
Query!
Country [14]
0
0
Hungary
Query!
State/province [14]
0
0
Budapest
Query!
Country [15]
0
0
Hungary
Query!
State/province [15]
0
0
Debrecen
Query!
Country [16]
0
0
Israel
Query!
State/province [16]
0
0
Jerusalem
Query!
Country [17]
0
0
Israel
Query!
State/province [17]
0
0
Tel Aviv
Query!
Country [18]
0
0
Korea, Republic of
Query!
State/province [18]
0
0
Busan
Query!
Country [19]
0
0
Korea, Republic of
Query!
State/province [19]
0
0
Daegu
Query!
Country [20]
0
0
Lithuania
Query!
State/province [20]
0
0
Kaunas
Query!
Country [21]
0
0
Lithuania
Query!
State/province [21]
0
0
Vilnius
Query!
Country [22]
0
0
Netherlands
Query!
State/province [22]
0
0
Amsterdam
Query!
Country [23]
0
0
Norway
Query!
State/province [23]
0
0
Loerenskog
Query!
Country [24]
0
0
Poland
Query!
State/province [24]
0
0
Warszawa
Query!
Country [25]
0
0
Spain
Query!
State/province [25]
0
0
Barcelona
Query!
Country [26]
0
0
Spain
Query!
State/province [26]
0
0
Valencia
Query!
Country [27]
0
0
United Kingdom
Query!
State/province [27]
0
0
Hull
Query!
Country [28]
0
0
United Kingdom
Query!
State/province [28]
0
0
Newcastle Upon Tyne
Query!
Country [29]
0
0
United Kingdom
Query!
State/province [29]
0
0
Oxford
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Intercept Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Study to evaluate the efficacy, safety, and tolerability of investigational drug obeticholic
acid (OCA) in combination with the investigational drug bezafibrate (BZF) in participants
with Primary Biliary Cholangitis (PBC).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04594694
Query!
Trial related presentations / publications
Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology. 2009 Jul;50(1):291-308. doi: 10.1002/hep.22906. No abstract available.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009 Aug;51(2):237-67. doi: 10.1016/j.jhep.2009.04.009. Epub 2009 Jun 6. No abstract available.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Antonio Civitarese, M.D.
Query!
Address
0
0
Intercept Pharmaceuticals, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04594694
Download to PDF